OakChart

Icecure Medical Ltd

ICCMHealthcare·Medical Devices·Israel·Nano·NASD·Nov 11 • 9:56 AM ET

0.8000+0.0100 (1.27%)
2026-11-11 15:56 CET
Market cap
2.71 USD m
Revenue, TTM
3.95 USD m
Net income, TTM
-16.88 USD m
Free cash flow, TTM
-17.01 USD m
EPS diluted, TTM
-6.57
P/E
-
Compare

Price

ICCM against its 20, 50 and 200-day averages
2050200beat
0.005.0010.0015.0020.0076.5M152.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ICCMclose 0.8020-day 0.9250-day 1.41200-day 7.170.80

96.6% under 23.50 on 4 Nov 2025. Last 15 sessions, 72.3% high to low

Profile

ICCM
52-week range, 1% of the way up
0.6522.50

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Employees69
IPONov 07, 2013
Beta0.52
ATR, 14d0.12
Rel volume1.91
Short float3.69%
Insider own55.60%
Inst own14.31%

Snapshot

6 groups

Valuation

Index-
Market Cap2.74M
Enterprise Value-9.20M
Income-16.88M
Sales3.95M
Book/sh3.47
Cash/sh3.51
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees69
IPONov 07, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S0.69
P/B0.23
P/C0.23
P/FCF-
EV/EBITDA-
EV/Sales-2.33
Quick Ratio2.44
Current Ratio2.87
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-6.57
EPS next Y-3.66
EPS next Q-1.16
EPS this Y25.69%
EPS next Y31.59%
EPS next 5Y32.04%
EPS past 3/5Y19.27% 32.65%
Sales past 3/5Y3.08% -2.67%
EPS Y/Y TTM20.47%
Sales Y/Y TTM41.62%
EPS Q/Q22.14%
Sales Q/Q72.76%
EarningsAug 12 BMO
EPS/Sales Surpr.-1.87% -37.46%

Ownership

Insider Own55.60%
Insider Trans0.00%
Inst Own14.31%
Inst Trans15.74%
ROA-119.31%
ROE-228.31%
ROIC-141.65%
Gross Margin36.10%
Oper. Margin-423.69%
Profit Margin-427.67%
SMA20-12.91%
SMA50-43.36%
SMA200-88.84%
Trades-

Technical

Shs Outstand3.43M
Shs Float1.52M
Short Float3.69%
Short Ratio0.36
Short Interest0.06M
52W High22.50 -96.44%
52W Low0.65 23.08%
Volatility13.44% 10.85%
ATR (14)0.12
RSI (14)30.85
Beta0.52
Rel Volume1.91
Avg Volume156.17K
Volume33,754

Performance

Perf Week1.19%
Perf Month-27.27%
Perf Quarter-73.33%
Perf Half Y-88.75%
Perf YTD-95.63%
Perf Year-96.14%
Perf 3Y-96.46%
Perf 5Y-99.57%
Perf 10Y-98.30%
Recom1.00
Target Price19.00
Prev Close0.79
Price0.80
Change %1.27%

Peers

Mkt cap
TickerCompanyMkt cap
BDMDBaird Medical Investment Holdings Limited3.48M
ADGMAdagio Medical Holdings Inc1.57M
PROFProfound Medical Corp281.50M
DCTHDelcath Systems Inc757.02M
SRTSSensus Healthcare Inc54.90M
TLSITriSalus Life Sciences Inc161.94M
NVCRNovoCure Ltd1.42B
CATXPerspective Therapeutics Inc97.12M
ATRCAtricure Inc2.88B
STXSStereotaxis Inc87.21M

News

latest 14 of 103
  • IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026 (PR Newswire)
  • IceCure Medical Secures New Chinese Patent for Cryogenic Technology Connector (InvestorsHub) +20.82%
  • IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio (PR Newswire)
  • IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation (PR Newswire)
  • IceCure enrols initial patients for ProSense cryoablation trial in US (Medical Device Network)
  • Loading…
  • IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites (PR Newswire)
  • IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026 (PR Newswire)
  • IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site (PR Newswire) -17.53%
  • IceCure Medical Receives Regulatory Approval to Market ProSense in China (PR Newswire)
  • IceCure Signs Exclusive Distribution Agreement for ProSense Cryoablation Systems in the Netherlands (PR Newswire) -6.58%
  • West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation (PR Newswire)
  • Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as US ... (GuruFocus.com)
  • IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-1.545-1.517-1.4600.911.453
2026Q12026-05-12-1.800-1.400-1.7430.911.343
2025Q42026-03-17-1.800-1.500-1.7501.301.301
2025Q32025-11-19-1.800-1.500-1.7690.850.712
2025Q22025-08-13-1.800-1.932-1.6870.530.662
2025Q12025-05-28-1.767-2.355-1.8320.730.752
2024Q42025-03-27-2.400-2.250-2.3730.881.072
2024Q32024-11-26-2.400-2.250-2.3740.660.712
2024Q22024-08-20-1.800-2.100-1.8421.010.932
2024Q12024-05-28-2.400-2.301-2.2730.741.023
2023Q42024-04-03-1.800-2.100-1.9301.261.173
2023Q32023-11-15-2.700-2.700-2.5810.331.023
2023Q22023-08-14-2.700-2.601-2.5090.920.933
2023Q12023-05-22-2.400-2.799-2.4310.710.953
2022Q42023-03-29-3.201-3.099-3.3000.941.003
2022Q32022-12-05-3.300--3.3000.62-1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-10.200-10.200-10.2034.123.90
2022FY-13.725-13.425-13.5013.093.47
2023FY-9.600-9.525-9.4513.233.14
2024FY-8.928-8.340-8.8633.293.49
2025FY-7.200-6.900-7.2003.383.40
2026FY--5.350--4.30
2027FY--3.660--6.98
2028FY--2.260--22.32
2029FY-0.410--44.93
2030FY-2.980--68.17

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-262000.880.850.90
2026Q3S2026-08-202020.880.850.90
2026Q3S2026-08-123021.040.851.38
2026Q3S2026-07-263001.801.003.02
2026Q3S2026-05-123111.801.003.02
2026Q3S2026-05-013001.861.233.02
2026Q3S2026-04-212002.121.233.02
2026Q3S2026-03-262012.121.233.02
2026Q3S2026-03-172012.121.233.00
2026Q3S2026-02-021001.231.231.23
2026Q3S2026-01-071101.231.231.23
2026Q3S2025-11-192104.871.238.50
2026Q3S2025-11-112004.751.018.50
2026Q3S2025-11-103003.671.018.50

Estimate history

EPS, annual-13.73-9.325-10.026-51.28-10.203-13.501-9.451-8.863-7.105-6.5746
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.842-2.374-2.373-1.832-1.687-1.769-1.75-1.743-1.314
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.6661.1231.6113.8684.1383.0853.2293.2913.3793.95
Period201720182019202020212022202320242025TTM
Sales, quarterly1.0110.6620.8750.7250.5250.851.2790.9110.907
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.2040.4320.510.0861.2161.551.5541.9222.4373.427
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.6821.8611.9221.9911.9942.2992.4372.7063.427
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3.953.383.293.233.084.143.871.611.12
Cost of Goods Sold Incl. D&A2.522.271.991.931.641.941.421.170.68
Gross Profit1.431.111.301.301.452.192.440.440.44
Selling, General and Administrative Excl. Other18.1516.2017.0016.8318.1811.926.595.143.90
Research and Development8.347.437.108.279.125.883.812.912.15
Other Operating Expense0.000.000.000.050.000.000.000.000.00
Operating Income-16.72-15.09-15.70-15.58-16.74-9.72-4.14-4.70-3.45
Interest Expense0.16---0.240.170.040.030.07
Unusual Expense0.000.000.000.000.00-0.220.170.29
Net Income Before Taxes-16.88-15.06-15.32-14.65-16.98-9.90-3.73-4.64-3.70
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-16.88-15.06-15.32-14.65-16.98-9.90-3.73-4.64-3.70
Net Income From Continuing Operations-16.88-15.06-15.32-14.65-16.98-9.90-3.73-4.64-3.70
Net Income-16.88-15.06-15.32-14.65-16.98-9.90-3.73-4.64-3.70
EPS (Recurring)-4.93-7.10-8.86-9.45-13.50-10.20-51.28-9.77-8.81
EPS (Basic, Before Extraordinaries)-6.57-7.10-8.86-9.45-13.50-10.20-51.28-10.03-9.33
EPS (Diluted)-6.57-7.10-8.86-9.45-13.50-10.20-51.28-10.03-9.33
EBITDA-16.44-14.80-15.36-15.25-16.49-9.60-4.08-4.55-3.42
Non-Operating Income (Expense)0.000.040.380.920.000.000.410.260.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-1.370.871.311.870.320.230.350.17
Price To Sales Ratio4.2211.4817.0115.1218.6021.041.1112.8516.62
Gross Margin36.1032.8239.6540.2646.8453.0463.1927.2839.44
Operating Margin-423.69-446.70-476.94-482.38-542.59-234.99-107.08-291.97-307.51
Net Margin-427.67-445.61-465.45-453.76-550.34-239.13-96.43-288.00-329.70
Shares Outstanding3.432.441.921.551.551.220.090.510.43
Market Capitalization2.712.7163.4249.7558.1698.7641.2323.279.67

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.910.911.280.850.530.720.880.66
Cost of Goods Sold Incl. D&A0.650.620.680.570.390.510.460.43
Gross Profit0.250.290.600.280.130.220.420.23
Selling, General and Administrative Excl. Other4.684.544.824.113.523.884.944.53
Research and Development2.072.212.301.761.711.661.701.87
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.42-4.25-4.22-3.84-3.38-3.66-4.53-4.29
Interest Expense0.080.030.030.02----
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-4.50-4.27-4.25-3.86-3.36-3.59-4.48-4.15
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.50-4.27-4.25-3.86-3.36-3.59-4.48-4.15
Net Income From Continuing Operations-4.50-4.27-4.25-3.86-3.36-3.59-4.48-4.15
Net Income-4.50-4.27-4.25-3.86-3.36-3.59-4.48-4.15
EPS (Recurring)-1.31-1.74-1.75-1.77-1.69-1.83-2.37-2.37
EPS (Basic, Before Extraordinaries)-1.31-1.74-1.75-1.77-1.69-1.83-2.37-2.37
EPS (Diluted)-1.31-1.74-1.75-1.77-1.69-1.83-2.37-2.37
EBITDA-4.35-4.18-4.14-3.76-3.32-3.57-4.44-4.21
Non-Operating Income (Expense)0.000.000.000.000.020.070.050.14
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Sales Ratio4.226.2113.1422.3320.9720.7018.578.55
Gross Margin27.8932.3846.9132.5924.9530.0747.6635.50
Operating Margin-487.76-466.19-329.63-451.29-644.76-504.41-517.14-648.49
Net Margin-496.25-469.15-331.98-454.00-640.76-494.90-511.89-626.74
Shares Outstanding3.432.712.442.301.991.991.921.86
Market Capitalization2.7124.4444.6170.0059.5570.2463.4234.06

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments8.907.5611.0623.9525.628.175.794.231.46
Short Term Receivables0.330.220.100.200.580.170.100.250.06
Inventories2.621.992.272.861.961.060.720.660.30
Other Current Assets0.750.980.741.122.160.190.300.060.04
Total Current Assets12.6110.7514.1828.1330.329.596.925.191.86
Net Property, Plant & Equipment1.231.782.192.021.630.610.380.070.04
Total Investments and Advances0.050.000.000.000.000.000.020.020.02
Intangible Assets0.00----0.000.000.000.00
Other Assets0.000.050.030.030.330.040.020.010.01
Total Assets13.8912.5816.4130.1932.2810.247.345.301.93
Short Term Debt Incl. Current Port. of LT Debt0.200.300.220.170.220.210.130.000.94
Accounts Payable0.861.230.500.710.880.650.430.460.15
Other Current Liabilities3.763.983.153.462.922.853.070.720.48
Total Current Liabilities4.825.513.874.344.023.713.641.181.57
Long Term Debt0.010.160.380.430.690.120.110.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities0.000.000.000.000.620.760.350.000.00
Total Liabilities4.845.674.254.775.324.594.091.181.57
Non-Equity Reserves0.000.000.000.000.000.000.610.730.62
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity9.056.9012.1625.4226.965.652.633.39-0.26
Total Shareholders Equity9.056.9012.1625.4226.965.652.633.39-0.26
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity9.056.9012.1625.4226.965.652.633.39-0.26
Total Liabilities & Stockholders Equity13.8912.5816.4130.1932.2810.247.345.301.93
Book Value Per Share3.713.597.8316.4022.1865.785.167.86-1.26
Tangible Book Value Per Share3.713.597.8316.4022.1865.785.167.86-1.26
Full-Time Employees697277655535312419
Price to Book Ratio0.239.193.363.0819.368.988.844.604.60
Return on Assets-113.79-105.69-62.89-54.36-46.42-42.45-73.46-102.43-105.97
Return on Equity-188.78-160.70-77.97-64.83-62.73-90.09-153.98-236.10-301.29
Return on Invested Capital-166.12-216.91-116.85-65.67-35.80-64.69-169.10-109.10-
Quick Ratio2.071.593.085.837.062.301.703.860.99
Current Ratio2.611.953.666.497.542.581.904.421.18

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-17.99-15.06-15.32-14.65-16.98-9.90-3.73-4.64-3.70
Depreciation0.300.300.330.320.250.130.060.150.03
Other Funds (Non Cash)1.361.260.911.292.220.32-0.220.300.45
Funds from Operations-16.32-13.50-14.08-13.04-14.51-9.45-3.89-4.19-3.22
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.61-1.071.520.520.21-3.160.202.500.01
Cash from Operating Activities-16.94-14.57-12.56-12.52-14.29-12.61-3.69-1.69-3.21
Capital Expenditures-0.07-0.04-0.07-0.48-0.89-0.53-0.22-0.10-0.07
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.52-0.230.004.33-4.450.000.00
Purchase of Investments-5.30-5.00-1.39-0.530.00-0.30-4.450.000.00
Sale Or Maturity of Investments5.305.001.900.300.004.620.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.07-0.040.45-0.71-0.893.79-4.67-0.10-0.07
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock25.7415.839.190.0813.5830.895.863.287.26
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock25.7415.839.190.0813.5830.895.863.287.26
Proceedsfrom Stock Options25.4215.549.190.0013.5830.555.853.287.24
Issuance or Reduction of Debt, Net-2.010.000.000.000.000.000.000.00-0.97
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00-0.20-0.02
Other Financing Activities Uses0.000.000.000.000.000.000.00-0.20-0.02
Cash from Financing Activities23.7415.839.190.0813.5830.895.862.986.27
Exchange Rate Effect0.090.11-0.040.03-0.360.040.22-0.00-0.01
Net Change in Cash6.821.33-2.97-13.13-1.9622.12-2.291.182.98
Free Cash Flow-17.01-14.61-12.63-13.00-15.18-13.14-3.91-1.79-3.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments12.038.128.9010.015.386.04
Short Term Receivables0.410.270.330.100.120.30
Inventories2.542.652.622.712.332.04
Other Current Assets1.651.090.750.841.191.06
Total Current Assets16.6512.1212.6113.669.029.44
Net Property, Plant & Equipment1.011.131.231.371.521.62
Total Investments and Advances0.050.050.050.000.000.00
Intangible Assets0.000.000.00---
Other Assets0.000.000.000.050.050.04
Total Assets17.7113.3013.8915.0810.5911.10
Short Term Debt Incl. Current Port. of LT Debt0.070.130.200.262.310.27
Accounts Payable1.630.990.861.151.160.95
Other Current Liabilities4.093.683.764.334.173.77
Total Current Liabilities5.794.804.825.757.645.00
Long Term Debt0.020.010.010.020.060.11
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities5.814.814.845.777.705.10
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity11.908.499.059.312.896.00
Total Shareholders Equity11.908.499.059.312.896.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity11.908.499.059.312.896.00
Total Liabilities & Stockholders Equity17.7113.3013.8915.0810.5911.10
Book Value Per Share3.473.143.714.051.453.01
Tangible Book Value Per Share3.473.143.714.051.453.01
Full-Time Employees--69---
Price to Book Ratio0.232.884.937.5220.6011.71
Return on Assets-119.31-129.00-113.79-100.74-120.09-112.66
Return on Equity-228.31-217.23-188.78-157.91-230.80-173.47
Return on Invested Capital-37.77-50.29-46.84-41.36-114.03-58.74
Quick Ratio2.441.972.071.900.881.48
Current Ratio2.872.522.612.381.181.89

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.73-4.27-4.67-4.32-3.39-3.59
Depreciation0.070.070.080.080.060.09
Other Funds (Non Cash)0.100.180.100.990.090.17
Funds from Operations-4.55-4.03-4.49-3.25-3.24-3.33
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.46-0.24-0.970.140.40-0.71
Cash from Operating Activities-4.09-4.27-5.47-3.11-2.84-4.04
Capital Expenditures-0.01-0.05-0.01-0.00-0.02-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.005.23-5.230.000.00
Purchase of Investments0.000.00-0.07-5.230.000.00
Sale Or Maturity of Investments0.000.005.300.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.00-0.000.00
Cash from Investing Activities-0.01-0.055.22-5.23-0.02-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock8.073.544.1310.010.102.56
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock8.073.544.1310.010.102.56
Proceedsfrom Stock Options8.063.544.129.700.102.56
Issuance or Reduction of Debt, Net0.000.000.00-2.012.010.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities8.073.544.138.002.102.56
Exchange Rate Effect0.020.000.24-0.180.09-0.04
Net Change in Cash4.00-0.784.13-0.52-0.67-1.52
Free Cash Flow-4.10-4.32-5.47-3.12-2.86-4.04

Revenue breakdown

Disposables2024: 1.83M 2025: 2.05M
Exclusive Distribution Agreement2024: 100.00K
Systems2024: 1.36M 2025: 1.33M
China2024: 41.00K 2025: 108.00K
India2024: 413.00K 2025: 120.00K
Israel2024: 30.00K 2025: 24.00K
Japan2024: 481.00K 2025: 282.00K
Other Countries2024: 1.46M 2025: 1.94M
United States2024: 870.00K 2025: 908.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.69%0.1M1.5M144.75K
2026-10-152.78%0.0M1.5M142.10K
2026-09-303.43%0.1M1.5M152.74K
2026-09-156.75%0.1M1.5M3.31M
2026-08-317.09%0.1M1.5M3.27M
2026-08-144.53%0.0M0.9M3.29M
2026-07-312.45%0.0M1.5M3.27M
2026-07-157.27%0.1M1.5M3.32M
2026-06-3026.23%0.3M1.2M3.22M
2026-06-157.21%0.1M1.2M48.64K
2026-05-291.93%0.0M1.2M21.70K
2026-05-154.23%0.0M1.0M18.64K
2026-04-303.55%0.0M1.0M16.80K
2026-04-154.25%0.0M1.0M14.80K
2026-03-313.50%0.0M1.3M13.69K
2026-03-131.73%0.0M1.3M9.35K
2026-02-271.52%0.0M1.3M9.42K
2026-02-131.55%0.0M1.3M10.73K
2026-01-301.36%0.0M1.3M12.08K
2026-01-151.52%0.0M1.3M13.76K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-11-024Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-024Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-05SEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-05SEC
2026-09-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-28SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-08-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-24SEC
2026-08-18EFFECTEffectiveness filing by commission orderSEC
2026-08-18EFFECTEffectiveness filing by commission orderSEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-173Initial statement of beneficial ownership of securities2026-08-12SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-14S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-14SEC
2026-08-14SCHEDULE 13GSEC
2026-08-13POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-13POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-07-02EFFECTEffectiveness filing by commission orderSEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
StoneX Group Inc.1.72%
JANE STREET GROUP, LLC1.24%
Scientech Research LLC1.16%
Gunderson Capital Management LLC0.58%
HRT FINANCIAL LP0.54%
JPMORGAN CHASE & CO0.21%
MORGAN STANLEY0.15%
UBS Group AG0.09%
SBI Securities Co., Ltd.0.02%
Kingdom Financial Group LLC.0.02%

Funds

Fund% owned
Capital World Bond Fund213.77%
Dimensional International Core Fixed Income ETF92.64%
Capital World Bond Fund32.07%
iShares Core International Aggregate Bond ETF14.25%
Fidelity Nasdaq Composite Index Fund0.06%

OakChart. ICCM. Cached 15 minutes.

Some panels did not load: ratings, insider.